{"id":7188,"date":"2024-11-21T16:01:52","date_gmt":"2024-11-21T15:01:52","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7188"},"modified":"2025-04-29T11:54:57","modified_gmt":"2025-04-29T09:54:57","slug":"tislelizumab-versus-docetaxel-in-patients-with-previously-treated-advanced-nsclc-rationale-303-a-phase-3-open-label-randomized-controlled-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-versus-docetaxel-in-patients-with-previously-treated-advanced-nsclc-rationale-303-a-phase-3-open-label-randomized-controlled-trial\/","title":{"rendered":"Tislelizumab Versus Docetaxel in Patients With\u00a0Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-7188","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7188"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}